CONMED Corporation (CNMD) insider have most recently took part in a trading activity. On Jan 3, 2018 Farkas Charles, Director bought 158 shares having total worth of $7,996 at the price of $50.61 per share, following the transaction a total of 11,707 shares owned by Farkas Charles. Before this latest buy, Farkas Charles purchased CNMD at 3 other times during the past twelve months, for a total investment of $29,584 at an average of $46.61 per share.
The stock has experienced a total of 2 insider trades in the past three months. These trades include 2 sell activities .Furthermore, over the past 12 months , the stock was traded 11 times by insiders. In 5 of these trades, the insider was a seller while an employee of the company was the buyer in 6 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of CONMED Corporation (CNMD) traded up 1.05% on Jan 3, 2018, hitting $51.14. 114,966 shares of the company’s stock traded hands. CONMED Corporation has a 52 week low of $37.75 and a 52 week high of $54.24. The company’s market cap is $1,110 million.
CONMED Corporation (CNMD) last announced its earnings results on Nov 2, 2017. The company reported 0.42 earnings per share (EPS) for the quarter, higher than the consensus estimate of 0.41 by $0.01. The company had revenue of $190 million for the quarter, compared to the consensus estimate of $187 million. During the same quarter in the previous year, the company posted 0.41 earnings per share. The company’s revenue for the quarter was up 3% on a year-over-year basis.
|earnings per share||0.42||0.00||0.41||0.38||0.54||0.41||0.47||0.42||0.52||0.38|
Conmed Corporation was incorporated under the laws of the State of New York in 1970. It is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and monitoring. The Company’s products serve the clinical areas of arthroscopy, powered surgical instruments, electrosurgery and cardiac monitoring disposables, endosurgery and endoscopic technologies. They are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. The Company conducts its business through five principal operating segments: CONMED Endoscopic Technologies, CONMED Endosurgery, CONMED Electrosurgery, CONMED Linvatec and CONMED Patient Care. CONMED Endosurgery, CONMED Electrosurgery and CONMED Linvatec segments product offerings include a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic procedures, electrosurgical generators and related surgical instruments, arthroscopic instrumentation for use in orthopedic surgery and small bone, large bone and specialty powered surgical instruments. CONMED Patient Care segment product offerings include a line of vital signs and cardiac monitoring products including pulse oximetry equipment & sensors, ECG electrodes and cables, cardiac defibrillation & pacing pads and blood pressure cuffs. It also offers a complete line of reusable surgical patient positioners and suction instruments & tubing for use in the operating room, as well as a line of IV products. CONMED Endoscopic Technologies segment product offerings include a comprehensive line of minimally invasive endoscopic diagnostic and therapeutic instruments used in procedures which require examination of the digestive tract. The Company’s products are distributed domestically directly to more than 6,000 hospitals and other healthcare institutions as well as through medical specialty distributors and surgeons. The Company manufacture substantially all of its products and assemble them from components, many of which it produce. The Company uses numerous raw materials and components in the design, development and manufacturing of its products. The Company’s competitors are Smith & Nephew, plc, Arthrex, Inc., Stryker Corporation, ArthroCare Corporation, Johnson & Johnson: DePuy Mitek, Inc., Biomet, Inc., Medtronic, Inc. Midas Rex and Xomed divisions, Synvasive Technology, Inc., Synthes, Inc., MicroAire Surgical Instruments, LLC, 3M Company, ERBE Elektromedizin GmbH, Covidien Ltd, Johnson & Johnson: Ethicon Endo-Surgery, Inc., Boston Scientific Corporation – Endoscopy, Wilson-Cook Medical, Inc., Olympus America, Inc., and U.S. Endoscopy. The Company’s operations are subject to a number of environmental laws and regulations governing, among other things, air emissions, wastewater discharges, the use, handling and disposal of hazardous substances and wastes, soil and groundwater remediation and employee hea
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018